> Are drug manufacturers still spending more on marketing than on drug production? Mostly, yes. (This data[1] is from 2015, but likely not too far off what's

> Are drug manufacturers still spending more on marketing than on drug production? Mostly, yes. (This data[1] is from 2015, but likely not too far off what's happening today.). > Don't they spend a good deal on simply trying to make a drug to work around someone else's IP, rather than making drugs where there is a new benefit -- that might account for most of the R&D for all I can tell, it doesn't appear to be included in this analysis? Honestly, not so much. The big money these days is in drugs which offer a transformational benefit over the current standard of care - whether that SoC is another marketed drug (either from the same company, or another) or a not very good treatment (or treatments) that no-one has improved upon yet. [1] https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/?utm_term=.f7f3cc15084a https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p...